"Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.
Patients with LAL deficiency (also known as Wolman disea"...
For poliovirus prophylaxis:
Adults: 0.5 mL PO initially, then repeated 8 weeks later. The third dose should be given 8-12 months after the second dose. When less than 4 weeks is available before immunization is required, a single 0.5 ml PO dose should be given.
Infants: The first 0.5 ml PO dose should be administered at 6-12 weeks of age. The second 0.5 ml PO dose should be administered preferably 8 weeks after the first dose. The third 0.5 ml PO dose should be administered at 6 months of age, however, if this time cannot be met, the third dose may be administered as late as 18 months of age. Children up to age 18 years: 0.5 mL PO initially, followed by the second dose preferably 8 weeks after the first dose. The third dose is given 8-12 months after the second dose (adolescents and older children may receive the third dose 6-8 weeks after the second dose if there is an increased risk of poliomyelitis). Booster doses are suggested upon starting school at 4-6 years of age, unless the third dose of the primary series was given after the recipient's fourth birthday.
Patients with renal impairment:
Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
DOSAGE AND ADMINISTRATION
Poliovirus vaccine live oral, OPV is administered orally. OPV must not be administered parenterally.
May be administered directly into the mouth using the single-dose pipette supplied by the manufacturer. Alternatively, mix with distilled or chlorine-free water, syrup, or milk, or adsorbed on bread, cake, or sugar cube.
If a dose is not swallowed, spat out, or a substantial portion is regurgitated or vomited shortly after administration (i.e., within 5-10 minutes), a second dose should be given. If the second dose is not retained, do not count either dose, readminister on the next visit.
No Information ProvidedThis monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/8/2004
Additional Orimune Information
Report Problems to the Food and Drug Administration
Find out what women really need.